Global glomerulonephritis market analysis (2026–2030) with strategic insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Glomerulonephritis Market Compare Between 2026 And 2030?

The glomerulonephritis market has experienced steady expansion over recent years. It is anticipated to expand from $11.61 billion in 2025 to $12.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.0%. The increase observed in previous periods can be linked to the rising prevalence of autoimmune disorders, the wider adoption of kidney biopsy, the expansion of nephrology clinics, the availability of immunosuppressive drugs, and the growth in diagnostic laboratory facilities.

The glomerulonephritis market size is anticipated to demonstrate consistent growth in the coming years. It is projected to increase to $14.66 billion by 2030, achieving a compound annual growth rate (CAGR) of 4.7%. This growth during the forecast timeframe is attributable to developments in renal diagnostics, the evolution of precision nephrology, a rising prevalence of chronic kidney disease, an expansion of specialized nephrology care, and enhanced treatment adherence. Key trends within the forecast period comprise a greater emphasis on early kidney disease diagnosis, an increasing utilization of immunosuppressive therapies, a broader adoption of biomarker-based testing, an expansion of dialysis support services, and improved management of chronic diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

Which Strong Drivers Are Impacting The Glomerulonephritis Market Growth?

The increasing occurrence of kidney disorders is anticipated to boost the expansion of the glomerulonephritis market in the future. Kidney disorders describe various conditions that impair kidney structure or function, affecting filtration, waste removal, and fluid balance. The growing prevalence of these disorders stems from factors like aging populations, a rise in chronic illnesses such as diabetes and hypertension, and certain lifestyle choices. These disorders contribute to glomerulonephritis by causing immune system dysfunction, persistent inflammation, or structural damage, which compromises kidney filtration and function. For instance, in June 2023, Kidney Research UK reported that approximately 7.19 million individuals in the UK suffered from chronic kidney disease in 2023, constituting over 10% of the UK population, with projections indicating an increase to 7.61 million people by 2033. Consequently, the rising incidence of kidney disorders is set to propel the growth of the glomerulonephritis market.

How Is The Glomerulonephritis Market Broken Down By Segment Categories?

The glomerulonephritis market covered in this report is segmented –

1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

Which Trends Are Contributing To Changes In The Glomerulonephritis Market?

Leading firms within the glomerulonephritis market are concentrating on creating innovative non-immunosuppressive treatments, aiming to fulfill unmet medical requirements and enhance patient results. These non-immunosuppressive treatments represent therapies designed not to impair or inhibit the immune system, thereby seeking to manage conditions without affecting its normal operation. As an illustration, in September 2024, Travere Therapeutics Inc., a biopharmaceutical firm based in the US, launched FILSPARI (sparsentan), which received approval from the Food and Drug Administration (FDA) for the management of IgA nephropathy, a specific kidney disorder. This medication stands as the sole non-immunosuppressive therapy proven to considerably decelerate the deterioration of kidney function in individuals afflicted with the condition. The endorsement of FILSPARI signifies a substantial advancement in addressing IgA nephropathy, recognized as the most prevalent form of primary glomerulonephritis. This therapeutic approach provides a novel alternative for patients whose prior treatment selections were restricted. Such approval underscores Travere’s dedication to betterment of patient outcomes within the realm of kidney diseases.

Which Players Are Present In The Glomerulonephritis Market Space?

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

Get The Full Glomerulonephritis Market Report:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

Which Region Dominates The Glomerulonephritis Market By Market Share?

North America was the largest region in the glomerulonephritis market in 2025. The regions covered in the glomerulonephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Glomerulonephritis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

Browse Through More Reports Similar to the Global Glomerulonephritis Market 2026, By The Business Research Company

Diabetic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795